Mechanism of Action
Cortagen follows the Khavinson BCPP mechanism of targeted gene expression modulation in organ-specific tissues.
Chromatin Binding in Cardiomyocytes
Cortagen's tetrapeptide sequence binds gene promoter regions in cardiac-specific chromatin, upregulating cytoprotective and metabolic genes in cardiomyocytes. This includes upregulation of antioxidant enzymes, mitochondrial respiratory chain components, and anti-apoptotic factors relevant to cardiac ischemia survival.[1]Coronary Vascular Protection
Cortagen promotes endothelial cell survival and reduces oxidative stress in coronary vasculature. It normalizes coronary tone and reduces coronary vasospasm in experimental models, contributing to improved myocardial perfusion.[2]Anti-Ischemic and Anti-Arrhythmic Properties
In myocardial ischemia-reperfusion models, Cortagen reduces infarct size, decreases arrhythmia incidence, and improves post-ischemic contractile recovery. These protective effects appear to be mediated through both direct cytoprotective gene upregulation and anti-inflammatory signaling.[1]Research Overview
Myocardial Ischemia Protection
Most StudiedCortagen consistently reduces infarct size in experimental myocardial ischemia models. In rat ischemia-reperfusion studies, Cortagen pre-treatment reduces infarct area by 30-50% and reduces ventricular arrhythmia frequency. Cardiomyocyte survival markers (Bcl-2/Bax ratio) improve significantly with Cortagen.[1]
Cardiac Aging
Moderate EvidenceAged animal hearts show improved functional parameters (contractility, relaxation time, coronary reserve) with Cortagen treatment. Age-related mitochondrial dysfunction in cardiomyocytes is partially reversed. Cortagen is used in Russian geriatric cardiology for age-related cardiac decline.[2]
Combination with Epithalon
Moderate EvidenceCombined Cortagen + Epithalon protocols in aged animals show additive benefits on cardiac function and lifespan metrics compared to either peptide alone. This combination is used in some Khavinson anti-aging protocols for cardiovascular-focused interventions.[2]
Calculate your Cortagen dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Cardiac support / anti-aging | 5–10 mg | Once daily × 10 days | Subcutaneous |
| Combined with Epithalon | 5 mg Cortagen + 10 mg Epithalon | Once daily × 10 days (concurrent) | Subcutaneous |
Morning dosing. 10-day courses 2-3 times per year. Same course-based protocol as Epithalon and Pinealon. Can be run concurrently with other Khavinson bioregulators (Epithalon, Pinealon, Thymulin) during the same 10-day course.
Research protocols only. Not medical advice.
Peptide Interactions
Safety Profile
Cortagen shares the favorable safety profile of the Khavinson peptide bioregulator series.
No significant adverse effects: Multiple preclinical studies and Russian clinical observational data show no toxicity, hematological abnormalities, or organ damage at research doses.
Very small molecule: The tetrapeptide size limits immunogenicity risk.
Course-based only: All long-term data uses 10-day courses rather than continuous daily dosing. Continuous use safety is not established.
No FDA approval: Used in Russia as pharmaceutical. Research compound in Western markets.
References
- [1]Khavinson VKh, et al. "Tetrapeptide Cortagen reduces the ischemic zone size in experimental myocardial infarction." Bull Exp Biol Med. 2002;134(3):249-251.
- [2]Anisimov VN, Khavinson VKh. "Peptide bioregulation of aging: results and prospects." Biogerontology. 2010;11(2):139-149.